Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

PHOX2B is a suppressor of neuroblastoma metastasis.

Naftali O, Maman S, Meshel T, Sagi-Assif O, Ginat R, Witz IP.

Oncotarget. 2016 Mar 1;7(9):10627-37. doi: 10.18632/oncotarget.7056.

2.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777. Epub 2015 Jan 5.

3.

A 6-gene signature identifies four molecular subgroups of neuroblastoma.

Abel F, Dalevi D, Nethander M, J├Ârnsten R, De Preter K, Vermeulen J, Stallings R, Kogner P, Maris J, Nilsson S.

Cancer Cell Int. 2011 Apr 14;11:9. doi: 10.1186/1475-2867-11-9.

4.

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK; International neuroblastoma Risk Group Task Force.

Br J Cancer. 2009 May 19;100(10):1627-37. doi: 10.1038/sj.bjc.6605029. Epub 2009 Apr 28.

5.

Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Cheung IY, Feng Y, Gerald W, Cheung NK.

Clin Cancer Res. 2008 Nov 1;14(21):7020-7. doi: 10.1158/1078-0432.CCR-08-0541.

6.

Models, mechanisms and clinical evidence for cancer dormancy.

Aguirre-Ghiso JA.

Nat Rev Cancer. 2007 Nov;7(11):834-46. Review.

Supplemental Content

Support Center